SAFETY AND EFFICACY OF ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (MAGNOLIA PHASE 2 STUDY). (17th June 2021)

• Record Type: Journal Article
• Authors: Trotman, J.; Tedeschi, A.; Linton, K.; McKay, P.; Hu, B.; Chan, H.; Jin, J.; Sobieraj‐Teague, M.; Zinzani, P. L.; Coleman, M.; Browett, P.; Ke, X.; Sun, M.; Marcus, R.; Portell, C.; Thieblemont, C.; Zhou, K.; Liberati, A. M.; Bachy, E.; Cavallo, F.; Costello, Rég.; Iyengar, S.; Marasca, R.; Mociková, H.; Kim, J. S.; Talaulikar, D.; Co, M.; Zhou, W.; Huang, J.; Opat, S.
• Is Part Of: Hematological oncology. Volume 39(2021)Supplement 2
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-06-17
• Subjects: Indolent non‐Hodgkin lymphoma; Hematological oncology -- Periodicals; Hematology; Medical Oncology; 616.99418005
• DOI: 10.1002/hon.19_2880
• Languages: English
• ISSNs: 0278-0232